Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).

Key facts

Study ID
NCT03601637
Run by
Vertex Pharmaceuticals Incorporated
People needed
61
Starts
2018-09-07
Expected to finish
2021-10-29
Last updated by the study team
2023-01-06

Who can join

Age: 1 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.